Previous clinical observations in favor of EMP3 as a TSG in gliomas were based on EMP3 gene expression and knockdown studies, as well as on the demonstration of EMP3 hypermethylation as marker of poor outcome in neuroblastoma patients [5, 10]. This evidence concerns the gene EMP3 and neuroblastoma.